PHAR
NASDAQPharming Group N.V. ADS each representing 10
SectorHealth CareIndustryBiotechnology: Pharmaceutical Preparations
Price$12.67-3.17 (-20.01%)
2026-03-092026-06-10
News · 26 weeks31+20%
2025-12-142026-06-07
Mix2190d
- Other9(43%)
- SEC Filings9(43%)
- Earnings2(10%)
- Analyst1(5%)
Latest news
25 items- SECSEC Form 6-K filed by Pharming Group N.V. ADS each representing 106-K - Pharming Group N.V. (0001828316) (Filer)
- PRPharming announces U.S. FDA acceptance of sNDA resubmission for Joenja® (leniolisib) to treat children aged 4 to 11 years with APDSIf approved, Joenja will be the first approved treatment in the U.S. for children with activated phosphoinositide 3-kinase delta (PI3Kδ) syndrome (APDS), a rare primary immunodeficiency Supplemental New Drug Application (sNDA) resubmission seeks approval for 40 mg and 50 mg twice-daily dosingSeparate sNDA for lower weight pediatric patients planned for second half 2026 Leiden, the Netherlands, June 4, 2026: Pharming Group ((Euronext: PHARM, NASDAQ:PHAR) today announced that the U.S. Food and Drug Administration (FDA) has accepted its resubmitted supplemental New Drug Application (sNDA) seeking approval for Joenja® (leniolisib), an oral, selective phosphoinositide 3-kinase delta (PI3Kδ) inhi
- PRPharming Group to participate in Fireside Chat at 2026 Jefferies Global Healthcare Conference in New YorkLeiden, the Netherlands, June 2, 2026: Pharming Group ("Pharming") (NASDAQ:PHAR) today announced its participation in the 2026 Jefferies Global Healthcare Conference in New York on June 3-4, 2026. Fabrice Chouraqui, Chief Executive Officer, will participate in a Fireside Chat Q&A session on Thursday, June 4 at 11:05am EDT/17:05 CEST. A live webcast and replay of the presentation will be made available in the "Events and presentations" and "Our news" sections of Pharming's website. For more information about the conference, or to schedule a one-on-one meeting with Pharming's management team, please contact Pharming's Investor Relations team at investor@pharming.com or your Jefferies repres
- SECSEC Form 6-K filed by Pharming Group N.V. ADS each representing 106-K - Pharming Group N.V. (0001828316) (Filer)
- SECSEC Form 6-K filed by Pharming Group N.V. ADS each representing 106-K - Pharming Group N.V. (0001828316) (Filer)
- PREuropean Commission grants marketing authorization to Pharming's Joenja® (leniolisib) – the first approved treatment for APDS in the European UnionJoenja® (leniolisib) is first approved treatment in the European Union for activated phosphoinositide 3-kinase delta (PI3Kδ) syndrome (APDS), a rare primary immunodeficiency, in adult and pediatric patients aged 12 years and olderFirst European launch expected in Germany in Q3 2026Approval adds to Joenja® approvals in the United States, United Kingdom, Japan, Australia and Israel, supporting Pharming's global expansion strategy Leiden, the Netherlands, May 22, 2026: Pharming Group ("Pharming" or "the Company") (NASDAQ:PHAR) today announced that the European Commission (EC) has granted marketing authorization for Joenja® (leniolisib), an oral, selective phosphoinositide 3-kinase (PI3K) delta
- SECSEC Form 6-K filed by Pharming Group N.V. ADS each representing 106-K - Pharming Group N.V. (0001828316) (Filer)
- SECSEC Form 6-K filed by Pharming Group N.V. ADS each representing 106-K - Pharming Group N.V. (0001828316) (Filer)
- PRPharming Group announces presentations at CIS 2026 Annual Meeting, including leniolisib pediatric data in APDS and clinical experience in CVID and related disordersLeiden, the Netherlands, May 7, 2026: Pharming Group N.V. ("Pharming" or "the Company") (NASDAQ:PHAR) today announced presentations at the 2026 Annual Meeting of the Clinical Immunology Society (CIS), taking place May 6-9 in New Orleans, LA. Across multiple presentations, the Company and its collaborators will share interim outcomes of a long-term extension study for leniolisib in pediatric patients aged 4 to 11 years with activated phosphoinositide 3-kinase delta (PI3Kδ) syndrome (APDS). The presentations will also include clinical data from expanded access use of leniolisib to treat immune dysregulation in patients with Common Variable Immunodeficiency (CVID) and CVID-like disorders, as
- PRPharming Group reports first quarter 2026 financial results; on track for Joenja® U.S. pediatric label expansion and launches in Japan and Europe in 2026First quarter 2026 total revenues were US$72.4 million, an 8% decrease compared to the first quarter 2025RUCONEST® revenue was US$58.4 million, a 15% decrease compared to the first quarter 2025, mainly due to anticipated inventory drawdowns and the planned exit from non-U.S. marketsJoenja® revenue was US$14.1 million, a 34% increase compared to the first quarter of 2025, reflecting strong U.S. and international momentumReaffirmed 2026 total revenue guidance of US$405 - US$425 million (8% - 13% growth)Generated positive net cash flow from operations of US$2.0 million in the quarterJoenja® approved in Japan and received positive CHMP opinion for APDSResubmitted pediatric sNDA to the FDA for Jo
- PRPharming Group to report first quarter 2026 financial results and provide business update on May 7Leiden, the Netherlands, April 23, 2026: Pharming Group N.V. ("Pharming" or "the Company") (NASDAQ:PHAR) confirms that it will report its preliminary (unaudited) financial results for the first quarter 2026 and provide a business update on Thursday, May 7, 2026. Management will host a conference call and webcast for analysts and investors on the same day at 13:30 CEST/07:30 am EDT. To participate in the conference call or to watch the live webcast, please register in advance using the links below. Conference call registration:https://register-conf.media-server.com/register/BI1dba0cdf00fd47289729b51369140831 Once registered, dial-in information and a unique PIN will be provided, allowi
- SECSEC Form 6-K filed by Pharming Group N.V. ADS each representing 106-K - Pharming Group N.V. (0001828316) (Filer)
- SECAmendment: SEC Form 20-F/A filed by Pharming Group N.V. ADS each representing 1020-F/A - Pharming Group N.V. (0001828316) (Filer)
- ANALYSTCanaccord Genuity initiated coverage on Pharming Group N.V. with a new price targetCanaccord Genuity initiated coverage of Pharming Group N.V. with a rating of Buy and set a new price target of $37.00
- PRPharming Group to participate in April investor conferencesLeiden, the Netherlands, April 7, 2026: Pharming Group N.V. ("Pharming") (NASDAQ:PHAR) today announced that its management will participate in the following investor conferences in the month of April: 25th Annual Needham Virtual Healthcare Conference, April 13, 2026Fabrice Chouraqui, Chief Executive Officer, and Anurag Relan, Chief Medical Officer, will present on Monday, April 13 at 08:45 am ET/14:45 CET. A live webcast and replay of the presentation will be available in the "Upcoming Events" and "News" sections of Pharming's website.Van Lanschot Kempen Life Sciences Conference 2026, Amsterdam, NL, April 15, 2026 For more information about these conferences, or to schedule a one-on-one me
- SECSEC Form 6-K filed by Pharming Group N.V. ADS each representing 106-K - Pharming Group N.V. (0001828316) (Filer)
- SECSEC Form 20-F filed by Pharming Group N.V. ADS each representing 1020-F - Pharming Group N.V. (0001828316) (Filer)
- SECSEC Form 6-K filed by Pharming Group N.V. ADS each representing 106-K - Pharming Group N.V. (0001828316) (Filer)
- PRPharming Group receives positive CHMP opinion for Joenja® (leniolisib) for the treatment of APDS in adult and pediatric patients 12 years and olderIf approved, Joenja® (leniolisib) would become the first approved treatment in the European Union for activated phosphoinositide 3-kinase delta (PI3Kδ) syndrome (APDS), a rare primary immunodeficiencyDecision based on Phase II/III clinical data demonstrating statistically significant impact on measures of immune dysregulation and immunodeficiencyFinal European Commission decision expected in Q2 2026 Leiden, the Netherlands, March 27, 2026: Pharming Group N.V. ("Pharming" or "the Company") (NASDAQ:PHAR) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending marketing authorization for J
- SECSEC Form 6-K filed by Pharming Group N.V. ADS each representing 106-K - Pharming Group N.V. (0001828316) (Filer)
- PRPharming Group announces approval of Joenja® (leniolisib) in Japan for the treatment of APDS in patients aged 4 years and olderFirst approved treatment in Japan for activated phosphoinositide 3-kinase delta (PI3Kδ) syndrome (APDS)Approval is based on positive Phase III data from multinational and Japanese studies in patients aged 12 years and older and a multinational pediatric study in children aged 4 to 11 yearsFirst approval of Joenja covering children aged 4 to 11 with APDS Leiden, the Netherlands, March 24, 2026: Pharming Group N.V. ("Pharming" or "the Company") (NASDAQ:PHAR) today announced that Japan's Ministry of Health, Labour and Welfare (MHLW) has approved Joenja® (leniolisib), an oral, selective phosphoinositide 3-kinase (PI3K) delta inhibitor, for the treatment of activated PI3K delta syndrome (APDS) i
- SECSEC Form 6-K filed by Pharming Group N.V. ADS each representing 106-K - Pharming Group N.V. (0001828316) (Filer)
- PRPharming Group reports fourth quarter and full year 2025 financial results, delivering strong revenue growth and profitability with positive cash flowFull year 2025 total revenues increased by 27% to US$376.1 million, driven by continued growth of RUCONEST® and rising demand for Joenja® (leniolisib) Fourth quarter 2025 total revenues increased by 15% to US$106.5 million, compared to the fourth quarter 2024RUCONEST® full year revenue increased by 26% to US$317.9 million and fourth quarter revenue increased by 9% to US$86.7 millionJoenja® revenue increased by 29% to US$58.2 million and fourth quarter revenue increased by 53% to US$19.8 millionAchieved US$25.8 million operating profit in 2025, compared to a loss in 2024Achieved US$54.7 million net cash flow from operations in 2025, compared to negative cash flow in the prior year2026 total r
- PRPharming Group to report fourth quarter and full year 2025 financial results and provide business update on March 12Leiden, the Netherlands, February 26, 2026: Pharming Group N.V. ("Pharming" or "the Company") (NASDAQ:PHAR) confirms that it will report its preliminary (unaudited) financial results for the fourth quarter and full year 2025 and provide a business update on Thursday, March 12, 2026. Management will host a conference call and webcast for analysts and investors on the same day at 13:30 CET/08:30 am EDT. To participate in the conference call or to watch the live webcast, please register in advance using the links below. Conference call registration:https://register-conf.media-server.com/register/BIb3649a77439d4a2d8e5e002bac980cd1 Once registered, dial-in information and a unique PIN will
- PRPharming Group to present at the Oppenheimer 36th Annual Healthcare Life Sciences ConferenceLeiden, the Netherlands, February 17, 2026: Pharming Group N.V. ("Pharming" or "the Company") (NASDAQ:PHAR) today announced its participation in the Oppenheimer 36th Annual Healthcare Life Sciences Conference being held virtually on February 25-26, 2026. Fabrice Chouraqui, Chief Executive Officer, and Anurag Relan, M.D., Chief Medical Officer, will present on Wednesday, February 25 at 12:40pm ET/18:40 CET. A live webcast and replay of the presentation will be made available in the "Upcoming Events" and "News" sections of Pharming's website. To schedule a one-on-one meeting with Pharming's management team, please contact Investor Relations at investor@pharming.com or your Oppenheimer repres
PHAR FAQ
6 questionsWhat does Pharming Group N.V. ADS each representing 10 do?
Pharming Group N.V., a specialty pharmaceutical company, develops products for the treatment of rare diseases and unmet medical needs in the United States, Europe, and internationally. The company's lead product is Ruconest, a recombinant human C1 esterase inhibitor that is used for the treatment of acute hereditary angioedema. It also engages in the development of rhC1INH for the treatment of pre- eclampsia, acute kidney injury, and COVID-19; leniolisib, a phosphoinositide 3-kinase delta (PI3K delta) to treat patients with activated activated PI3K delta syndrome; and alpha-glucosidase...Where does PHAR stock trade?
Pharming Group N.V. ADS each representing 10 (PHAR) is listed on NASDAQ.What sector and industry is PHAR in?
Pharming Group N.V. ADS each representing 10 operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.What are analysts saying about PHAR?
Pharming Group N.V. ADS each representing 10 has had 2 recent analyst actions on file. The most recent action was from Canaccord Genuity: Buy with a $3700.00 price target on 2026-04-10. Recent price targets range from $1400.00 to $3700.00.What companies are similar to PHAR?
Notable peers in the same industry include LLY (Eli Lilly and Company), JNJ (Johnson & Johnson), AZN (AstraZeneca PLC), ABBV (AbbVie Inc.), MRK (Merck & Company Inc.). Compare PHAR side-by-side with any of them on Quantisnow.How can I track PHAR on Quantisnow?
Quantisnow aggregates Pharming Group N.V. ADS each representing 10's SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow PHAR to receive live email and push alerts on every new disclosure.